Capsaicin may slow PSA doubling time: case report and literature review.
Capsaicin may slow PSA doubling time: case report and literature review.
复制标题
DOI：
10.5489/cuaj.784
复制
发表时间：
2013-04
期刊：
影响因子：
--
通讯作者：
Bojana Jankovic;D. Loblaw;R. Nam
中科院分区：
文献类型：
--
作者：
Bojana Jankovic;D. Loblaw;R. Nam
辣椒素是辣椒的主要辛辣成分。据我们所知，这是第一例描述前列腺癌患者在放射治疗后出现生化失败，但前列腺特异性抗原（PSA）稳定的病例。2001年4月，一名66岁男性因T2 b，Gleason 7（3+4）前列腺癌接受放射治疗，PSA水平为13.3 ng/mL。他对前列腺和骨盆进行了23次46戈伊的三维适形放射治疗，并对15次30戈伊的前列腺进行了增强治疗。放疗于2001年5月完成，PSA于2002年1月降至最低点（0.57）。由于PSA持续升高，患者于2005年7月开始接受比卡鲁胺（50 mg口服，每日一次）和醋酸亮丙瑞林（1剂22.5 mg肌内注射）治疗，当时PSA为38.5 ng/mL。由于雄激素消除治疗的耐受性差，患者停止治疗，并于2006年4月开始服用2.5 mL含有辣椒素的哈瓦那辣椒酱料，每周1 - 2次。前列腺特异性抗原倍增时间（PSAdt）从辣椒素前的4周增加到2006年10月的7.3个月。从2006年10月至2007年11月，患者继续使用辣椒素（每日2.5 - 15 mL），PSA稳定（11 - 14 ng/mL）。到2008年1月，他的PSA上升到22.3，他保持了4到5个月的PSAdt，目前仍然如此。由于患者的PSA持续升高，他重新开始接受比卡鲁胺（12.5 mg每日一次）治疗。除了PSA复发，患者仍然没有复发的体征或症状。
Capsaicin is the main pungent component of chili peppers. This is the first case, to our knowledge, that describes prostate-specific antigen (PSA) stabilization in a patient with prostate cancer, who had biochemical failure after radiation therapy. A 66-year-old male underwent radiotherapy treatment for a T2b, Gleason 7 (3+4) adenocarcinoma of the prostate, with a PSA level of 13.3 ng/mL in April 2001. He had 3-dimensional conformal radiotherapy of 46 Gy in 23 fractions to the prostate and pelvis, and a prostate boost of 30 Gy in 15 fractions. Radiotherapy was completed in May 2001 and PSA nadired in January 2002 (0.57). Due to the continued PSA rise, the patient was started on bicalutamide (50 mg orally, daily) and leuprolide acetate (1 dose of 22.5 mg intramuscularly) in July 2005 when PSA was 38.5 ng/mL. Due to poor tolerance of androgen ablation therapy, the patient discontinued treatment and started taking 2.5 mL of habaneros chili sauce, containing capsaicin, 1 to 2 times a week in April 2006. Prostate-specific antigen doubling time (PSAdt) increased from 4 weeks before capsaicin to 7.3 months by October 2006. From October 2006 until November 2007, the patient remained on capsaicin (2.5 to 15 mL daily) and his PSA was stable (between 11 to 14 ng/mL). By January 2008, his PSA rose to 22.3 and he has maintained a PSAdt between 4 and 5 months, where it presently remains. Due to the patient's continued PSA rise, he was restarted on bicalutamide (12.5 mg daily). Apart from PSA relapse, the patient remains free of signs or symptoms of recurrence.